← Back to Search

Protein Supplement

Pea Protein for Obesity

N/A
Waitlist Available
Led By Peter Zahradka, PhD
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks
Awards & highlights

Study Summary

This trial looks at whether pea protein can help people lose weight without losing muscle mass.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in muscle function (gait test)
Change in muscle function (hand grip)
Change in muscle mass
Secondary outcome measures
24 h activity patterns over time
Change in C-reactive protein
Change in blood lipid profile
+12 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Pea ProteinExperimental Treatment1 Intervention
Participants will consume pea protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
Group II: Whey ProteinActive Control1 Intervention
Participants will consume whey protein (0.35 grams protein/kg body weight/day) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.
Group III: MaltodextrinPlacebo Group1 Intervention
Participants will consume maltodextrin (isocaloric non-protein comparator) as a powder incorporated into foods or beverages at least twice per day for 12 weeks.

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor
594 Previous Clinical Trials
199,382 Total Patients Enrolled
18 Trials studying Obesity
2,080 Patients Enrolled for Obesity
Peter Zahradka, PhDPrincipal InvestigatorSt. Boniface Hospital Albrechtsen Research Centre
4 Previous Clinical Trials
364 Total Patients Enrolled
1 Trials studying Obesity
150 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who can participate in this clinical research program?

"Applicants hoping to be accepted into this trial must have a diagnosis of obesity and fall within the 30-50 age range. A total of 72 patients are sought for enrolment."

Answered by AI

Is this clinical experiment still recruiting research participants?

"Affirmative. As indicated on clinicaltrials.gov, this trial is still recruiting patients to participate. It was initially posted in October 2019 and most recently updated July 25th 2022; the study requires 72 participants from a single research centre."

Answered by AI

Does the research project accept participants above 25 years of age?

"This trial is open to patients aged 30-50. For those outside this age range, there are 209 trials for individuals below 18 and 689 studies specifically targeting seniors over 65 years of age."

Answered by AI

What beneficial results are expected from this clinical examination?

"The primary measure of efficacy for this trial, evaluated over a Baseline and 12 week time frame, is an alteration in muscle mass. Additionally, changes to the blood lipid profile (total cholesterol levels, LDL-cholesterol levels, HDL-cholesterol levels and triglyceride values), systolic/diastolic blood pressure readings, as well as resting energy expenditure will also be measured."

Answered by AI

How many individuals are currently participating in this experiment?

"Affirmative. According to clinicaltrials.gov, this medical experiment is actively accepting participants since the posting of its announcement on October 17th 2019 and last edit made on July 25th 2022. 72 volunteers are required for participation in a single site."

Answered by AI
~11 spots leftby Apr 2025